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Abstract
Background: In a recent phase II clinical trial for HNSCC patients, IRX-2, a cell-derived biologic, promoted T-cell infiltration
into the tumor and prolonged overall survival. Mechanisms responsible for these IRX-2-mediated effects are unknown. We
hypothesized that IRX-2 enhanced tumor antigen-(TA)-specific immunity by up-regulating functions of dendritic cells (DC).
Methodology/Principal Findings: Monocyte-derived DC obtained from 18 HNSCC patients and 12 healthy donors were
matured using IRX-2 or a mix of TNF-a, IL-1b and IL-6 (‘‘conv. mix’’). Multicolor flow cytometry was used to study the DC
phenotype and antigen processing machinery (APM) component expression. ELISPOT and cytotoxicity assays were used to
evaluate tumor-reactive cytotoxic T lymphocytes (CTL). IL-12p70 and IL-10 production by DC was measured by LuminexH
and DC migration toward CCL21 was tested in transwell migration assays. IRX-2-matured DC functions were compared with
those of conv. mix-matured DC. IRX-2-matured DC expressed higher levels (p,0.05) of CD11c, CD40, CCR7 as well as LMP2,
TAP1, TAP2 and tapasin than conv. mix-matured DC. IRX-2-matured DC migrated significantly better towards CCL21,
produced more IL-12p70 and had a higher IL12p70/IL-10 ratio than conv. mix-matured DC (p,0.05 for all). IRX-2-matured
DC carried a higher density of tumor antigen-derived peptides, and CTL primed with these DC mediated higher cytotoxicity
against tumor targets (p,0.05) compared to the conv. mix-matured DC.
Conclusion: Excellent ability of IRX-2 to induce ex vivo DC maturation in HNSCC patients explains, in part, its clinical benefits
and emphasizes its utility in ex vivo maturation of DC generated for therapy.
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Introduction
Dendritc cells (DC) are specialized, highly potent antigen
presenting cells (APC) that are capable of inducing primary
immune responses in vivo [1]. In cancer patients, the DC frequency
and functions are decreased, and these defects account, at least in
part, for suppression of tumor antigen (TA)-specific immune
responses seen in these patients [2]. DC functions in cancer
patients seem to be impaired in multiple ways [2]. DC showing an
immature phenotype (iDC) with reduced abilities to prime T cell
responses were present in patients with colorectal and breast
cancer [3,4]. In HNSCC patients, accumulations of these iDC
correlated with a poor prognosis [5,6]. These iDC express low
levels of co-stimulatory molecules, and thus may not be able to
provide signal 2 necessary for priming of T-cell responses.
However, little attention has been paid to the ability of DC from
cancer patients to process and present TA, a process involving the
components of the antigen processing machinery (APM), which is
required for the delivery of signal 1 in the induction of primary T-
cell responses.
The APM consists of several intracellular proteins responsible
for processing, transport and chaperoning of peptides derived
mostly, but not exclusively, from endogenous proteins for cross-
presentation. After cleavage of these proteins by the proteasome
subunits, LMP-2 and LMP-7, the subunits of the transporter
associated with antigen processing (TAP), TAP1 and TAP2,
transport peptides into the endoplasmic reticulum (ER) [7].
TAP1/TAP2 complexes are then brought into contact with b2-
microglobulin (b2m)-HLA class I heavy chain complexes by
tapasin [7]. Before trimeric HLA class I heavy chain-b2m-peptide
complexes are transported to the cell surface, proper folding
catalyzed by the chaperone molecules, BiP, calnexin, calreticulin,
and ERp57, takes place in the ER [8]. HLA class I peptide
complexes on the cell surface of APC are recognized by CD8+ T
lymphocytes bearing cognate T cell receptors [8]. Recent studies
suggest that up-regulation of the APM component expression
correlates with the improved ability of DC to cross-present
antigens and to cross-prime cytolytic T lymphocytes (CTL) [9,10].
Yet, APM component expression and its contribution to DC
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function in cancer patients have been evaluated only to a limited
extent.
Impaired DC functions observed in cancer patients could
potentially contribute to tumor escape by negatively regulating
anti-tumor T cells [2]. Thus, it would be desirable to correct DC
impairments and restore anti-tumor activity of T cells in vivo.
Systemic delivery of cytokines, e.g., GM-CSF or IFN-a2b to
patients with cancer is aimed at the restoration of DC functions
and the generation of more robust anti-tumor T-cell responses
[11,12]. Therefore, IRX-2, a cell-derived biologic containing a
well-defined mix of cytokines, was recently administered to the
HNSCC patients enrolled in a phase II clinical trial. IRX-2 was
injected locoregionally in the adjuvant setting with an expectation
that it might enhance DC function in vivo [13]. The results showed
a significant infiltration of tumors with activated T cells after IRX-
2 therapy which was associated with prolonged overall survival
(OS) [14]. We have previously reported that IRX-2 is able to up-
regulate HLA-DR, CD86, CD40 and CCR7 expression and
induce IL12p70 production, a cytokine necessary for Th1
polarization, in monocyte-derived DC generated from PBMC of
healthy donors (HD) [15]. Although, we attributed the observed
positive correlation between T-cell infiltration and OS to
improved functions of DC after IRX-2 delivery, no information
is available about the mechanisms through which the treatment of
DC with IRX-2 might up-regulate T-cell anti-tumor activity.
Here, we evaluate in vitro effects of IRX-2 on DC and, specifically,
on the APM component expression in these cells which determines
their potential to present TA to T cells. Our data show that IRX-2
not only enhances functions in mDC obtained from cancer
patients and HD, but that it does so more efficiently than the
conventional mix of IL-6, IL-1 and TNF-a broadly used for DC
maturation. Thus, IRX-2 might be potentially beneficial as an
immune therapeutic and a maturation biologic for the production
of therapeutic DC.
Results
Purity and Phenotype of iDC of Cancer Patients and HD
The purity of iDC from patients and HD was evaluated by
microscopic cell counts (morphology) and by flow cytometry (FS/
SS properties). DC preparations routinely contained $80% of
cells with DC morphology, and cell viability routinely exceeded
90% as determined by a trypan blue exclusion test. Table S1,
shows that the phenotype of iDC generated from monocytes
obtained from HD and HNSCC are not different. However, as
shown in Figure S1A and S1B, intracytoplasmic staining of iDC
for various APM components revealed a significantly lower
expression (p,0.01) of TAP1 and TAP2 in iDC of HNSCC
patients relative to that in iDC of HD. The differences were
selective since expression of LMP2, Tapasin and Calreticulin was
not significantly different in iDC of HNSCC patients as compared
to iDC of HD.
Distinct Phenotype of DC Matured by IRX-2 vs. a
Conventional Maturation Cocktail
A widely used conventional combination of cytokines for DC
maturation consists of TNF-a, IL-1b and IL-6. We compared it
with IRX-2 after 48 h of maturation, which results in maximal
effects as determined in preliminary studies (data not shown). Both
procedures resulted in a significant upregulation of all DC surface
markers, including the maturation markers CCR7, CD80 and
CD83. However, several differences were observed in the
phenotype of mDC derived from monocytes of the same patients
but matured either conventionally or by IRX-2 as shown in
Figure 1. The conventionally matured mDC had higher expres-
sion of CD80, CD83 (p,0.01) and CD86 (p,0.05) than the IRX-
2-matured DC. On the other hand, the IRX-2-matured DC
expressed significantly higher levels of CCR7 (p,0.01), CD11c
(p,0.01) and CD40 (p,0.05) than conventionally matured mDC.
As shown in Figure 1, total MHC-Class I and HLA-DR molecules
were up-regulated to a similar extent in DC matured with IRX-2
and conventional cytokines. Similar results were obtained when
using DCs from HD (data not shown).
IRX-2-matured DC Produce Higher Levels of IL-12p70
than Conventionally-matured DC
IL-12p70 production by DCs and the IL-12p70/IL-10 ratio
have been used as surrogate markers to predict the in vivo
potency of mDC. Therefore, we tested iDC, IRX-2-matued and
conventionally matured DC for their ability to produce IL-12p70
and IL-10. In iDC supernatants, IL-12p70 or IL-10 were not
detected (data not shown). Upon maturation in the conventional
cocktail or in IRX-2, DC produced detectable levels of both IL-
12p70 and IL-10 (Table 1). However, IRX-2-matured DC
produced higher levels (p,0.05) of IL-12p70 and lower levels of
IL-10 (p= 0.071) than those matured with conventional cyto-
kines. As shown in Table 1, the IL-12p70/IL-10 ratio was
significantly greater in the supernatant of IRX-2-matured DC
(2.7 vs. 1.4, p,0.05). Interestingly, we observed that DC of HD
secreted higher total levels of IL-12p70 (p,0.01) as well as IL-10
than those of HNSCC patients, while the IL-12p70/IL-10 ratios
were similar to those seen in HNSCC patients for both
maturation cocktails (Tab. 2, 3.0 for IRX-2 and 1.8 for the
conventional cocktail).
Higher Numbers of IRX-2-matured than Conventionally-
matured DC Migrate Towards CCL21
To determine the functional significance of a higher percent-
age of CCR7+ cells present in IRX-2-matured than convention-
ally-matured DC, we tested the ability of DC to migrate towards
CCL21. In a transwell migration assay, mDC of HNSCC
patients generated in the presences of IRX-2 had a greater
capability to migrate (p,0.01) than iDC or mDC exposed to the
conventional cytokine cocktail. As shown in Figure 1C, iDC
showed very little migration towards CCL21, while IRX-2-
induced mDC of the same donors migrated considerably better.
In turn, mDC generated in the conventional cytokine mixture
migrated less efficiently (mean cells 16,000 vs. 7900, p,0.01).
APM component expression is higher in IRX-2-matured
than conventionally-matured DC. Next, the intracellular
expression of APM components in DC matured conventionally
or with IRX-2 was compared. Both the conventional cytokine
cocktail and IRX-2 up-regulated the expression levels of the APM
components LMP2, TAP1, TAP2, Tapasin and Calreticulin as
compared to iDC from the same donors (the data for iDC are
shown in Figure S1). However, as shown in Figure 2, IRX-2
induced higher levels of LMP2, TAP1, TAP2 and Tapasin
(p,0.05 for all) in mDC than did conventional cytokines. No
significant differences in the expression of Calreticulin and surface
MHC Class I molecules were evident between mDC matured with
IRX-2 and the conventional mix.
IRX-2-matured DC Induce TA-specific CTL in vitro
The induction of TA-specific T cells (CTL) is the final and
critical endpoint of antigen presentation by mDC. In IVS
cultures, we generated CTL from PBMC of HLA-A2+ HNSCC
patients using mDC which were cultured in the presence of IRX-
IRX-2 Up-Regulates DC Maturation
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2 or conventional cytokines. Lysates of the HLA-A2+ HNSCC
cell line PCI-13 served as an antigen source in the IVS culture.
As shown in Figure 3, both conventional and IRX-2 matured
DC induced CTL which were able to kill PCI-13 target cells.
Anti-HLA class I blocking Abs inhibited cytotoxicity and CTL
showed only low cytotoxicity against the irrelevant target MCF-7
(data not shown). However, CTL generated in the presence of
IRX-2-matured DC showed higher cytotoxicity as compared to
CTL generated with conventional mDC. Taken together, IRX-
2-matured DC were more effective in inducing tumor cell-
specific CTL in vitro as compared to conventional mDC.
IRX-2 Matured DC Cross-present Antigen more Efficiently
than Conventionally-matured DC
Knowing that both conventionally- and IRX-2-matured DC are
able to cross-prime PCI-13 specific CTL populations, we decided
to use these in vitro generated CTL to explore the ability of mDC
to cross-present tumor antigens. As summarized in Figure 4A,
CTL were generated by IVS using mDC, which were either
matured by conventional cytokines (Conv CTL) or IRX-2 (IRX-2
CTL). PCI-13 HNSCC cells were used as an antigen source for
both types of CTL. DC matured either by IRX-2 or the
conventional cytokines were loaded with a PCI-13 cell-lysate
and tested for the presence of HLA-Class-I-peptide complexes on
their surface. These surface complexes were recognized by
autologous conventional CTL and IRX-2 CTL as shown in
Figure 1. Phenotype and migration of DC matured in IRX-2 or conventional cytokines. (A) DC obtained from HNSCC patients were
matured for 48 h either with IRX-2 or the conventional maturation cocktail. While conventionally matured DC (white bars) expressed higher levels of
CD80, CD83 and CD86 (*, p,0.05), IRX-2 matured DC (black bars) showed higher expression of CD11c, CD40 and CCR7 (*, p,0.05). The data are mean
x-fold of MFI 6 SEM for cells obtained from 12 different HNSCC patients. (B) Representative histograms showing expression of DC markers after
maturation with IRX-2 or the conventional cytokine cocktail in DC generated from monocytes of one HNSCC patient. The shaded peaks represent
isotype controls. (C) Migration of mDC in vitro: Migration assays were performed as described in Materials & Methods using DC generated from
peripheral blood monocytes of HNSCC patients. While iDC showed very little migration in response to CCL21, both conventional- and IRX-2-matured
DC migrated significantly better. Results are shown as the mean absolute numbers of migrated cells 6 SEM obtained from 5 different HNSCC
patients.
doi:10.1371/journal.pone.0047234.g001
IRX-2 Up-Regulates DC Maturation
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IFN-c ELISPOT assays. Importantly, phagocytosis of lysed tumor
cells was similar in both DC preparations (data not shown).
Figure 4B shows that IRX-2 CTL showed a higher number of
IFN-c spots when co-incubated with IRX-2-matured DC than
when incubated with conventional DC (p,0.05). The data suggest
that IRX-2-matured DC are able to cross-present antigens derived
from PCI-13 cells more efficiently than those matured with a
conventional cytokine mixture.
Discussion
IRX-2, a novel multi-component biologic, has been used for
therapy of patients with HNSCC in a phase II clinical trial [13].
The therapy consisted of perilymphatically-delivered IRX-2 in
combination with low-dose cyclophosphamide and a cyclooxy-
genase inhibitor, indomethacin, as well as zinc in a multivitamin
formulation [14]. This regimen, administered prior to surgery, was
Table 1. IL-12p70 and IL-10 secretion by moDC of HD and HNSCC patients matured with IRX-2 or the conventional maturation
cocktail.
Cytokine HD p-value
Conventional (mean
pg/ml/105 cells ±SEM)
IRX-2 (mean
pg/ml/105 cells ±SEM)
IL-12p70 25.465.9 40.367.4 ,0.05
IL-10 20.864.8 14.464.4 0.071
Ratio of mean IL-12p70/IL-10 1.4 2.7 ,0.05
HNSCC
IL-12p70 11.961.5 22.666.6 ,0.01
IL-10 8.164.3 6.462.9 0.24
Ratio of mean IL-12p70/IL-10 1.8 3 ,0.05
doi:10.1371/journal.pone.0047234.t001
Figure 2. APM expression in mDC. moDC from HNSCC patients were matured for 48 h either with IRX-2 or the conventional maturation cocktail.
(A) IRX-2-matured DC (black bars) expressed significantly higher levels of TAP1, TAP2, LMP2 and Tapasin than conventional DC (white bars, *, p,0.05).
APM expression was determined by flow cytometry. The data are mean x-fold of MFI 6 SEM for cells obtained from 12 different HNSCC patients.
doi:10.1371/journal.pone.0047234.g002
IRX-2 Up-Regulates DC Maturation
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shown to increase lymphocyte infiltration into the tumor and T-
cell activation in situ as compared to biopsy tissue obtained prior
to treatment [13]. It also induced relatively minor but significant
changes in the peripheral blood lymphocyte subsets [16]. Further,
overall survival (OS) was shown to be significantly improved in the
patients whose tumors were infiltrated with T cells [13]. In view of
this in vivo evidence for mobilization and activation of T-cells by
IRX-2, and their correlation with improved OS, we considered
the possibility that IRX-2 enhanced TA processing and presen-
tation by DC, thereby resulting in more effective anti-tumor
immunity. We tested this hypothesis using DC derived from
monocytes of HNSCC patients and, specifically, evaluating IRX-2
effects on the expression of the APM components and on TA
presentation to T cells. It is well documented that only adequately
matured DC are able to cross-prime T cells and that only mDC
migrate to lymph nodes where they can prime T-cell responses
[17,18]. Further, mDC produce higher levels of IL12p70, the
cytokine necessary for Th1 and CTL responses, than iDC
[15,17,19]. In addition, maturation greatly enhances antigen
presentation and APM component expression as well as the
expression of co-stimulatory molecules on the surface of DC
[10,17,20]. Therefore, optimal maturation is essential DC
function.
Various combinations of cytokines and/or toll-like-receptor
(TLR) ligands have been used to mature human monocyte-derived
DC [17,21]. Usually, these cocktails contain variable levels of
multiple cytokines, e.g., 50 ng/ml TNF-a, 25 ng/ml IL-1b and
10 ng/ml IL-6 in the most widely used conventional cocktail (‘‘the
conv. mix’’). In contrast, IRX-2 used in this study contained 15–60
times lower concentrations of these cytokines (Table S2) than the
conv. mix. In direct comparisons, while the conv. mix induced
higher expression levels of CD80, CD83 and CD86 on moDC,
IRX-2 induced considerably higher expression levels of CCR7,
CD11c and CD40. Importantly, IRX-2-matured DC not only
expressed higher surface levels of CCR7 but also migrated better
in response to the CCR7 ligand, CCL21. CCR7 is essential for
Figure 3. Cytotoxicity of CTL generated in IVS cultures. CTL
were induced and expanded using iDC and DC matured either with IRX-
2 or the conventional cocktail from HLA-A2+ HNSCC patients. CTL
primed by conventionally-matured or IRX-2-matured DC were more
effective than CTL primed with iDC. CTL generated using IRX-2-matured
DC showed higher cytotoxicity than those primed with conventional
DC. Blocking MHC-class-I recognition with the mAb w6.32 abrogated
cytotoxicity. The data are mean percentages 6 SEM of specific killing at
different E:T ratios obtained from 4 independent experiments.
doi:10.1371/journal.pone.0047234.g003
Figure 4. Cross-presentation of lysed tumor cells by mDC. CTL were generated using either IRX-2- or conventionally-matured mDC (IRX-2 CTL
or conv CTL) as described in Materials and Methods. ELISPOT assays were performed using either IRX-2- or conventionally-matured mDC loaded with
lysed PCI13 and co-incubated for 24 h with IRX-2 CTL or conv CTL. The highest number of spots was observed when IRX-2 mDC were co-incubated
with IRX-2 CTL from the same donor (p,0.05 as compared to the other possible combinations of CTL and mDC). Co-incubation of IRX-2 mDC with
conv CTL or conv mDC with IRX-2 CTL led to a similar number of spots, while co-incubation of conv CTL with conv mDC led to a significantly lower
number of spots. IRX-2 and conv CTL showed similar levels of IFN-c release in the absence of mDC (white bars). The mean number of spots per 105
CD8+ T cells 6 SEM from 4 independent experiments is shown.
doi:10.1371/journal.pone.0047234.g004
IRX-2 Up-Regulates DC Maturation
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DC migration to lymph nodes, where interaction of DC and T
cells takes place [22], suggesting that IRX-2-matured DC might
also migrate more efficiently in vivo. CD40, a member of the
TNFR superfamily, serves as a receptor on DC which interacts
with CD154 on CD4+ T cells, leading to further DC maturation,
and it induces IL-12p70 production [23]. It has been suggested
that DC expressing low levels of CD40 might induce tolerance
instead of immunity [24]. The induction of high levels of CD40 on
DC matured with IRX-2 indicates that these cells are unlikely to
induce tolerance, a clearly undesirable event in cancer patients
receiving immunotherapy. The function of CD11c, also known as
complement rector 4, remains less clear, but studies indicate its
role in cell adhesion but also in antigen presentation by DC [25].
A higher CD11c expression on IRX-2-matured DC than on
conventionally-matured DC could thereby contribute to their
superior antigen presentation and induction of CTL.
The APM expression in DC is necessary not only for the
presentation of antigens derived from self-proteins via the classical
cytosolic pathway but also for the effective cross-presentation of
exogenous antigens in the context of MHC class I molecules [8].
In patients with cancer, the APM component expression is
compromised, and its’ up-regulation is, therefore, desirable [10].
Remarkably, IRX-2 was found to be able to induce higher levels of
APM expression than the conv. mix. It has been reported that
cytokine mixtures containing INF-c are especially efficient in up-
regulating the APM component expression [9]. In contrast to the
conv. mix, IRX-2 contains INF-c which could explain the higher
levels of LMP2, TAP1, TAP2 and Tapasin expression in mDC.
On the other hand, IFN-c alone is not a sufficient maturation
signal for moDCs and only in combination with TLR or CD40
ligation enhances CCR7-driven DC migration and cytokine
production [18]. Since IRX-2 up-regulated DC migration and
IL-12p70 production, it is likely that a synergistic effect of INF-c
and other cytokines included in IRX-2 was responsible for the
observed effects.
Recently, Lopez-Albeitero et al reported that cross-presentation
of the MAGE3271-279 peptide correlated with TAP1 and TAP2
expression in APC in that higher expression of these APM
components resulted in more effective presentation of the peptide
to T cells [9]. In addition, it has been shown, that a higher density
of MHC-class-I-peptide complexes on the surface of APC leads to
more effective induction and expansion of the peptide-specific
CTL [26]. We hypothesized, that DC matured in the presence of
IRX-2 have a higher density of non-self-peptide-MHC Class I
complexes on their surface and thus are more efficient in loading,
transporting and presentation of these peptides. Indeed, using
tumor-reactive CTL generated via IVS with PCI-13-loaded DC
we showed that IRX-2 matured DC induced high-potency CTL.
Although we found higher levels of the co-stimulatory molecules
CD80 and CD86 on conventionally-matured DC, CTL generated
in IVS cultures with IRX-2-matured DC turned out to be more
effective in killing PCI-13 targets which served as an antigen
source for cross-priming. It also appears that CTL generated in
IVS with IRX-2-matured mDC, which have enhanced cross-
priming capabilities, are more responsive to tumor-derived
antigens in ELISPOT assays. These CTL gave the highest
number of IFN-c spots upon co-incubation with IRX-2-matured
DC presenting the antigen. We, therefore, suggest that the
superior cross-priming capacity of IRX-2 matured DC is due to
better cross-presentation of tumor cell-derived antigens likely
resulting from up-regulated expression of APM components. In
turn, this suggests that APM plays the central role in regulating the
density of tumor-derived peptides present on the surface of mDC
and that this step is of critical importance in the preparation of
DC-based anti-cancer vaccines. However, effective cross-priming
of T cells by APC is also critically dependant on cytokine-mediated
signaling (i.e., signal 3) [27]. IL-12p70 appears to be essential for
CTL priming by DC [19,28]. Okada et al. recently reported that
clinical responses to DC-based vaccines correlated with IL-12p70
production by the DC used for therapy [29]. In contrast, IL-10,
which is considered to be an inhibitory cytokine, has negative
effects on priming of T-cell responses [30]. A higher ratio of IL-
12p70/IL-10 in supernatants of IRX-2-matured DC suggests that
these DC are more likely to prime CTL responses.
Since IRX-2 clearly increases the in vitro potency of moDC
obtained from the peripheral circulation of cancer patients and
might also do so in vivo [13], it appears to be a promising
component of future DC-based anti-tumor vaccines. For vaccine
production, its ability to enhance IL-12p70 production, migratory
response to CCL-21, APM component expression and cross-
presentation of tumor antigens to T cells by DC are especially
important. In immunotherapy of cancer, IRX-2 delivery alone or
together with DC-based vaccines could be considered in future
randomized clinical trials to improve the efficacy of currently
available treatments.
Materials and Methods
Blood Samples
Peripheral blood was obtained from 18 HNSCC patients and
12 age and sex matched HD. Blood was drawn prior to therapy.
All subjects signed an informed consent approved by the
Institutional Review Board of the University of Pittsburgh
(IRB#991206). Patients were seen at the Outpatient Otolaryn-
gology Clinic between May 2010 and May 2011. Clinicopatho-
logical characteristics are listed in Table 2.
IRX-2
IRX-2 is a primary cell-derived biologic containing multiple
well-defined cytokines and produced by stimulation of human
peripheral blood mononuclear cells (PBMC) with phytohemag-
glutinin (PHA). IRX-2 production under cGMP has been
described previously [31]. The IRX-2 lot used for all the described
Table 2. Clinicopathologic characteristics of patients with
HNSCC who donated blood for this study.
Age (Range in years) 39–78
Sex
Male 13
Female 5
Total 18
Tumor Stage
T1 4
T2 10
T3 1
T4 3
Nodal Status
N1 1
N2 4
N3 0
doi:10.1371/journal.pone.0047234.t002
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experiments below contains several cytokines at the concentrations
shown in Table S1.
Antibodies
The following flourochrome-labeled monoclonal antibodies
(mAbs) purchased from Beckman Coulter (Brea, CA) were used:
anti-CD3-ECD, anti-CD8-FITC, anti-HLA-DR-FITC and
PeCy5, anti-CD3-FITC, anti-CD14-PeCy5, anti-CD11c-PeCy5,
anti-CD40-PE, anti-CD80-FITC, anti-CD83-FITC and PeCy5,
anti-CD86-PE. Anti-CCR7-FITC mAb was from R&D Systems
(Minneapolis, MN). Appropriate isotype controls were purchased
from Beckman Coulter and Beckton Dickinson.
The LMP2-specific mAb SY-1, the TAP1-specific mAb NOB-1,
the TAP2-specific mAb NOB-2, the calreticulin-specific mAb TO-
11 and the tapasin-specific mAb TO-3 were developed and
characterized as described [32–34]. mAb were purified from
ascitic fluid by sequential precipitation with ammonium sulphate
and caprylic acid [35]. The purity of mAb preparations was
assessed by SDS-PAGE. The activity of the mAb preparations was
monitored by testing with a lymphoid cell lysate in Western
blotting. Anti-HLA-A2 mAb, BB7.2 was used to determine HLA-
A2 expression [36]. The secondary Ab used in an indirect staining
procedure, FITC-conjugated goat anti-mouse IgG Abs were
purchased from Caltag Laboratories (Burlingame, CA). An anti-
human-MHC-Class I mAb (w6/32) was described previously [37].
Cell Lines
The HLA-A2+ head and neck squamous cell carcinoma
(HNSCC) cell line, PCI-13, generated in our laboratory as
previously described [38], and the HLA-A2+ breast cancer cell line
MCF-7 were cultured in plastic culture flasks (Costar, Cambridge,
CA) under standard conditions (37uC, 5% CO2 in air) using
RPMI1640 medium (Lonza, Walkersville, MD) supplemented
with 10% (v/v) FBS (Gibco-Invitrogen, Carlbad, CA). Cell
cultures were tested every 3 months for endotoxin and Mycoplas-
ma and were found to be negative.
Surface and Intracellular Staining for Flow Cytometry
Cells were incubated for 20 min on ice with human Fc-Block
(eBioscience, San Diego, CA) according to the manufacturer’s
instructions. Without washing, cells were stained as described
previously [23].
All antibodies were pre-titrated on freshly-harvested and
activated PBMC to determine optimal working dilutions.
Surface and intracellular staining of the various APM compo-
nents was performed as previously described [10]. Samples were
tested using a 4-color Beckman Coulter XL, and data were
analyzed using the Expo32-Software.
Isolation of PBMC and DC Culture
PBMC were isolated by centrifugation on Ficoll-Hypaque (GE
Healthcare, Uppsala, Sweden) from heparinized venous blood
drawn from HD or HNSCC patients. moDC were generated as
described previously [15]. Briefly, after isolation, 5–106106
PBMC were seeded onto 6-well-plates (Beckton Dickinson,
Franklin Lakes, NJ) in AIM V medium (Gibco-Invitrogen,
Carlsbad, CA) and incubated for 2 h. A small portion of PBMCs
was used for HLA-A2-typing by flow cytometry. Non-adherent
cells were removed and cryoperserved. Adherent cells were
resuspended in RPMI1640 medium (Lonza) containing
1000 IU/ml GM-CSF (Bayer, Seattle, WA), 1000 IU/ml IL-4
(Cellgenix, Freiburg, Germany) and 10% (v/v) FBS (Gibco-
Invitrogen) and were cultured for 5 days. On day 5, immature DC
(iDC) were either harvested and tested or used for maturation. To
mature iDC, IRX-2 or a conventional maturation cocktail [39]
containing TNF-a (50 ng/ml), IL-1b (25 ng/ml) and IL-6 (10 ng/
ml) (all cytokines from Cellgenix) diluted in ex vivo 10 medium
(Lonza) were added. Following 48 h incubation, mature DC
(mDC) were harvested and used for phenotypic and functional
studies.
IL-12p70 and IL-10 Luminex
IL-12p70 and IL-10 concentrations in cell supernatants were
determined by using commercially available Luminex kits
according to the manufacturer’s instructions (Invitrogen). IL-
12p70 and IL-10 concentrations were also measured in IRX-2
mixed 1:1 with cell culture medium to determine background
cytokine levels. Background cytokine levels were then subtracted
from experimental values.
In vitro Migration Assay
DC migration was investigated as previously described [21].
Briefly, the lower chamber of 24 trans-well plates (Corning Inc.,
Corning, NY) with polycarbonate membranes and 5 mm pore size
was filled with 200 ml of RPMI1640 media containing 10% FBS
and CCL21 (Peprotech, Rocky Hill, NJ) used at concentrations
ranging from 0 to 100 ng/ml. Next, mDC (16105/100 ml
medium) were seeded in the upper chamber, and plates were
incubated for 2 h at 37uC. Cells in the lower chamber were
counted using a Z1 Beckman Coulter particle counter.
In vitro Sensitization (IVS) of CD8+ T Cells
CTLs were induced as previously described [37]. Briefly, PCI-
13 cell lysates of were generated by 5 cycles of rapid freezing and
thawing. DCs from HLA-A2+ donors were pulsed with tumor cell
lysates for the last 24 h of maturation. Based on the number of
tumor cells before lysis, tumor cells were added to DC at a 3:1
ratio. TA-pulsed mDC were then irradiated (3000 rad) and
washed with PBS. Autologous CD8+ T cells were isolated from
cryopreserved PBMC by negative selection using magnetic bead
separations (Miltenyi, Auburn, CA) and added to the mDC at the
10:1 ratio. Cells were cultured in an atmosphere of 5% CO2 in air
at 37uC for 7 days in AIM-V media containing 10 ng/ml IL-7 and
10 ng/ml IL-21 (Peprotech) and 5% (v/v) FBS. On day 7, fresh,
tumor cell lysate-pulsed and irradiated mDC were added and
T cells were cultured for additional 7 days in AIM V containing
20 IU/ml IL-2 (Peprotech), 5 ng/ml IL-7, 10 ng/ml IL-21 and
5% (v/v) FBS. On day 14, cells were harvested and used for
functional studies.
Phagocytosis Assay
Phagocytosis of lysed tumor cells by DC was determined using
flow cytometry as previously described [40]. Briefly, PCI13 cells
were stained with 2 mMol carboxyfluorescein succinimidyl ester
(CFSE, Invitrogen) and extensively washed. Necrosis was induced
in PCI13 cells by 5 cycles of freeze/thawing. iDC were stained
with 4 mM PKH26 (Sigma-Aldrich) for 5 min at RT and washed
afterwards. Maturation was induced by adding IRX-2 and the
conventional maturation cocktail, each diluted 1:1 with medium.
Lysed, CFSE-labeled PCI-13 cells were added at the 1:3 ratio after
the first 24 h of maturation. Co cultures were harvested at
different time points after the addition of the lysed tumor cells and
phagocytosis was determined by flow cytometry by gating on
PKH26+ events and expressed as the percentage of CFSE+ events
within the PKH26 gate.
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Flow Cytometry Based Cytotoxicity Assay
CTL cytotoxicity was assessed by a modified flow cytometry
based assay [41]. Briefly, PCI-13 and MCF-7 cells were stained
with 2 mMol CFSE for 10 min at 37uC in the dark. Cells were
washed and co-incubated with CTLs at various effector to target
ratios for 4 h at 37uC. An aliquot of 1 mg/ml 7-amino-
actinomycin D (7-AAD, Invitrogen) was then added to each tube,
and the cells were incubated for an additional 20 min. Cells were
acquired for analysis on a Beckman Coulter XL cytometer,
detecting CFSE on FL1 and 7-AAD on FL4. Target cells were
identified as CFSE-positive, and the percentage of 7-AAD positive
target cells was determined. Target cells maintained for 4 h
without CTL served as a negative control, and target cells
incubated for 10 min at 56uC before a 4 h incubation served as a
positive control for 7-AAD staining. The percentage of cytotoxic
activity was calculated using the following formula: % specific
lysis = 7-AAD+ targets minus spontaneous 7-AAD+ targets. MCF-
7, a breast cancer cell line, was used as a specificity control in
cytotoxicity assays. The HLA-class-I restriction of the cytotoxicity
was tested by the preincubation of the target cells with 10 mg/ml of
mAb W6/32 [37].
IFN-c ELISPOT Assay
IFN-c ELISPOT assays were performed as previously described
[23]. Briefly, wells of 96-well-plates with nitrocellulose membrane
inserts were incubated with a capture anti-IFN-c mAb (clone
1D1K, Mabtech, Nacka, Sweden) for 24 h at 4uC. Plates were
washed, and the CTL (16105) generated in IVS assays as
described above were added to each well followed by mDC
(2.56104) pulsed with a tumor cell lysate. Plates were then
incubated for 24 h at 37uC. Next, cells were removed by extensive
washing, and a biotinylated secondary anti-IFN-c Ab (clone 7-B6-
1, Mabtech) was added for 2 h. After washing, plates were
incubated with the avidin-peroxidase complex reagent, and
aminoethylcabazole was added as a substrate. The reaction was
terminated after 5 min, and spots were counted by computer-
assisted image analysis (Zeiss ELISPOT 4.13.3, Jena, Germany).
Background values (spots from wells containing mDC alone) were
subtracted from experimental values (spots in wells containing
mDC and CTL).
Statistical Analysis
Data were analyzed using unpaired and paired students t tests.
The p values ,0.05 were considered significant.
Supporting Information
Figure S1 APM expression in iDCs from HD and
HNSCC patients. (A) Immature monocyte derived DCs
generated from PBMC of HD (white bars) express significantly
higher levels of TAP1 and TAP2 (*, p,0.01) than those generated
from PBMC of HNSCC patients (black bars). Tapasin, Calreti-
cullin and LMP2 expression was not significantly different in
HNSCC patients and HD. The DC APM expression was
determined by flow cytometry. The data are mean percentages
6 SEM of cells positive for the indicated marker on cells obtained
from 12 different HD and 12 HNSCC. (B) Representative
histograms showing APM expression in iDC from HD and
HNSCC patients. The shaded peaks represent isotype controls.
(JPG)
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